Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $34.4300 (-1.74%) ($33.4300 - $35.6200) on Thu. Feb. 15, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.54% (three month average) | RSI | 26 | Latest Price | $34.4300(-1.74%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -0.5% a day on average for past five trading days. | Weekly Trend | ADMS declines -6.7% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XBI(25%) IBB(22%) ARKK(18%) IWM(18%) IWO(18%) | Factors Impacting ADMS price | ADMS will decline at least -1.77% in a week (0% probabilities). VIXM(-12%) UNG(-10%) BNDX(-9%) UUP(-8%) TLT(-6%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.77% (StdDev 3.54%) | Hourly BBV | 0 () | Intraday Trend | -2.7% | | | |
|
1 - 5 Day Possible Target | $21.16(-38.54%) | Resistance Level | $37.34 | 5 Day Moving Average | $34.2(0.67%) | 10 Day Moving Average | $34.94(-1.46%) | 20 Day Moving Average | $37.34(-7.79%) | To recent high | -19.3% | To recent low | 28.9% | Market Cap | $974m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |